CSIMarket
 
Ensysce Biosciences Inc   (ENSC)
Other Ticker:  
 
 
Price: $0.9221 $-0.01 -1.105%
Day's High: $0.95 Week Perf: 4.67 %
Day's Low: $ 0.91 30 Day Perf: -43.08 %
Volume (M): 197 52 Wk High: $ 7.20
Volume (M$): $ 182 52 Wk Avg: $1.76
Open: $0.93 52 Wk Low: $0.46



 Market Capitalization (Millions $) 2
 Shares Outstanding (Millions) 2
 Employees -
 Revenues (TTM) (Millions $) 3
 Net Income (TTM) (Millions $) -20
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Ensysce Biosciences Inc
Ensysce Biosciences Inc is a biopharmaceutical company that focuses on developing novel drug delivery technologies and formulations. The company aims to address various challenges in the pharmaceutical industry, such as improving the bioavailability and efficacy of drugs, reducing side effects, and enhancing patient compliance.

Ensysce Biosciences utilizes its proprietary technology platforms to enhance the delivery of both small molecule drugs and large molecules, such as peptides and proteins. Their technologies include platforms like DuraGel and DuraSorb, which enable sustained and controlled release of drugs over an extended period of time.

The company's innovative drug delivery systems have the potential to revolutionize the treatment of various diseases, including pain management, addiction, cancer, and central nervous system disorders. With a focus on improving patient outcomes and quality of life, Ensysce Biosciences is constantly striving to develop safer, more effective, and convenient drug delivery solutions.


   Company Address: 7946 Ivanhoe Avenue La Jolla 92037 CA
   Company Phone Number: 263-4196   Stock Exchange / Ticker: NASDAQ ENSC
   ENSC is expected to report next financial results on March 29, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Ensysce Biosciences Inc

Ensysce Biosciences Inc's Revenue Skyrockets 136% in Q2 2023, but Profits Elude Despite Surge

Ensysce Biosciences Inc Reports Solid Revenue Growth in Q2 2023 Earnings Season, but Losses Widen
Ensysce Biosciences Inc, a major player in the pharmaceutical preparations sector, announced a remarkable increase in revenue for the second quarter of 2023, with a growth rate of 136.405% year on year. The company reported revenue of $0.49 million, which surpassed the expectations of industry analysts.
However, the positive news was mitigated by the fact that Ensysce Biosciences Inc also reported widening losses, reaching $-0.98 million in the same period. Despite this setback, Ensysce Biosciences Inc still outperformed most of its contemporaries within the Major Pharmaceutical Preparations sector, as they only experienced a business elevation of 2.14% compared to the second quarter of 2022.

Ensysce Biosciences Inc

Ensysce Biosciences Inc's Revenue Skyrockets by 182% in Q1 2023, Despite Extended Losses

Ensysce Biosciences Inc Reports Losses of $-2.08 per share
Ensysce Biosciences Inc has reported losses of $-2.08 per share for the fiscal time-frame closing on March 31, 2023, which is an extended loss compared to the previous year's reporting period. However, the company saw a significant improvement in its revenue, which doubled by 182.668% from $0.28 million in the previous reporting period. The income per share also improved from $-5.13 per share.
For the January to March 31, 2023, span, Ensysce Biosciences Inc logged a net loss of $-2.192 million, which is a significant drop compared to the net earnings of $18.157 million in a similar reporting period a year before.






 

Ensysce Biosciences Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com